Stages of Alzheimer’s Disease

A resident of Atlanta, Georgia, Eugene E Houchins III is the president and founder of the American Life Corp Fund. He enjoys college football, high school sports, and coaching little league in his free time. Eugene Houchins III is also in Alzheimer’s disease research.

Alzheimer’s disease is the most common type of dementia; it causes memory loss, confusion, changes in personality, and gradual loss of independence. It tends to develop slowly and worsen over the years, and in the final stage, people with Alzheimer’s disease may be unable to communicate with people or know what is going on around them.

Firstly, Alzheimer’s disease begins long before any symptoms become apparent, and this is called the preclinical stage. New imaging techniques can identify deposits of a protein called amyloid-beta, a hallmark of Alzheimer’s disease. Genetic tests can also tell you if you have a higher risk of developing Alzheimer’s. The capacity to detect these early deposits could be particularly useful in clinical trials and the future if new Alzheimer’s disease treatments are developed.

The second stage is the mild cognitive impairment stage, where mild changes in memory and thinking ability occur. However, it is important to note that not everyone with mild cognitive impairment has Alzheimer’s disease. This may be the slight amnesia that many people experience as they get older, but it may also cause concentration issues.

Subsequently, People with Alzheimer’s disease at the mild dementia stage become more confused and forgetful, requiring more assistance with everyday activities and self-care.

Lastly, the mental function continues to deteriorate in the late stages of Alzheimer’s disease, known as serious dementia, and the disease has a significant influence on movement and physical ability. Patients may generally lose bowel and bladder control, need help with all activities, and lose the ability to communicate effectively.

New Treatment Could Increase Survival Rates after Chemotherapy

Through his firm American Life Fund Corp., Eugene E. Houchins III helps his clients gain access to funds needed for things such as uninsured medical costs. Eugene E. Houchins III takes a professional interest in innovations that could improve the survival rate of cancer patients.

Persons with lymphoma and leukemia may one day benefit from new research that suggests using existing drugs to fight cancer in a new and potentially much more effective way can increase survival rates.

No method now exists for curing or removing these cancers. Patients often receive chemotherapy with the goal of killing all cancer cells, staving off the disease. Unfortunately, cancer cells often develop resistance to chemo during treatment, and the tumors are not eradicated.

Researchers are now looking at a class of drugs known as small molecule inhibitors that takes advantage of cancer cells’ need for healthy adjacent cells (called stroma cells) to survive. Isolating the stroma cells from the tumor robs it of necessary nutrients and the cancer cells die.

Until now, scientists have not known how to accomplish this, but a recent study demonstrates that proteins known as PKC-inhibitors can starve tumor cells by affecting the stromas. Previous researchers who attempted to strike cancer cells directly with PKC saw poor results.

Treating both tumor and stroma cells improved survival rates considerably – in one case extending the period by 90 percent when compared to targeting tumors only. It had the added benefit of fighting several types of leukemia and lymphoma.

If other researchers can replicate these results, the outlook for patients with lymphoma and leukemia will be brighter.